UAMY Trade Idea - Buy the Government Option: Weak Prices, Bigger Volumes, and a Policy Catalyst

Hook & thesis

United States Antimony (UAMY) has just gone through a painful reset: weak antimony prices and a surprise guidance cut pushed shares down sharply, but volumes remain robust and the company is the only major domestic primary antimony smelter. That combination - cash burn and missed sales on one side, strategic market position and government demand on the other - creates a directional, event-driven opportunity for traders willing to accept binary outcomes.

My base trade thesis is simple: buy a tactical position around current levels to capture a mid-term re-rate if (1) the company demonstrates consistent DLA deliveries and revenues from its defense pipeline, (2) antimony prices stabilize, or (3) management uses cash / buybacks in a way that supports EPS per share. The setup offers asymmetric upside relative to downside when sized modestly and stopped out quickly.

What the company does and why the market should care

United States Antimony operates primary smelting and processing for antimony, plus precious metals recovery and zeolite operations. Antimony is a small but strategically important metal used in ammunition primers, flame retardants, and some battery chemistries. UAMY's strategic relevance comes from being essentially one of the only domestic producers with smelting capability; that makes the company a natural recipient of defense and government-driven buying as Washington seeks to onshore critical mineral supply chains.

Recent operating reality - the numbers that matter

• Q2 sales were reported at $7.93 million, a notable miss that drove a sharp market reaction and prompted management to reduce full-year sales guidance from $125 million to $60-75 million.
• The company reported negative operating cash flow for the first half of 2026 - roughly -$20.7 million - and its reported free cash flow stands at -$71,281,943.
• UAMY is unprofitable on a GAAP basis: trailing EPS is -$0.11 and return on equity is negative at roughly -8.98%.
• Valuation metrics show the market pricing in a scarcity premium: market cap is about $698,956,025 and price-to-sales sits near 19.22, with price-to-book around 3.87.
• Operationally, the company has started DLA deliveries: the first Q2 shipments under a $245 million Defense Logistics Agency contract generated about $2.6 million from ~82,000 pounds, and management has disclosed roughly $57.3 million in orders received to date.
• Liquidity line items in the public metrics include a reported cash figure of $6.24 (presented in company ratios) and shares outstanding of ~149.67 million.

Technical and market-structure context

Trading activity remains elevated: average daily volume sits near ~7.5 million shares while recent intraday volume and short-volume prints show meaningful participation from both buyers and shorts. Short interest has been sizable - in the range of ~33 million shares on recent settlement dates - which creates potential for rapid squeezes if fundamentals re-accelerate or a positive news flow hits the tape.

Technically the stock is still below the short- and mid-term moving averages; the 10-day SMA is about $5.14 and the 50-day SMA is $5.92 while RSI sits below 40, so momentum is not yet constructive. That said, the stock has fallen back toward its 52-week low ($4.14) from a $19.71 peak and the setup is classic for a catalyst-driven mean reversion trade.

Valuation framing

At roughly $699 million market cap and a price-to-sales near 19.2, the market currently values UAMY like a high-margin technology or a royalty business rather than an unprofitable metals processor. That premium reflects two expectations: durable higher antimony prices and repeatable, sizeable government contracts. With trailing sales and cash flow weak, the existing valuation is conditional - it requires improvement in price realization or contract cadence to be justified.

Compare that to the company’s own history: the stock peaked near $19.71 as the market priced in strategic-mineral scarcity. The current valuation could be rational if management proves a steady, multi-quarter revenue stream from defense orders and margins improve as smelter utilization rises. If not, downside is meaningful.

Catalysts to watch (2-5)

• Additional DLA shipments and recognized revenue - steady monthly or quarterly deliveries that show repeatability and push backlog toward recognized sales.
• Antimony price stabilization or recovery - any visible lift in realized metal prices that narrows the gap between current selling prices and management targets.
• Execution on buybacks or capital allocation that meaningfully reduces share count - the announced $100 million repurchase program and insider buying are potential re-rating events if executed transparently and accretively.
• Sector-level moves such as government funding or loans for domestic projects - additional policy backing that accelerates onshore production would be a positive for UAMY's strategic narrative.

Bottom-line trade plan (actionable)

Thesis: Enter a tactical long for a mid-term re-rate that depends on contract cadence and price stability. This is a catalyst-driven swing with asymmetric upside but binary risk.

Rationale: entry near current trading levels ($4.73) provides a favorable payoff if the market re-prices UAMY toward a more normalized multiple after several positive DLA deliveries or if antimony prices firm. The stop at $3.80 limits downside to about 20% from entry; the target at $9.50 is achievable if the market resumes earlier valuation levels or if confirmed defense orders and improving prices push multiple expansion. Expect the trade to last roughly 45 trading days unless a clear change of fundamentals emerges sooner.

Position sizing: keep any allocation small relative to portfolio risk tolerance. With negative free cash flow and meaningful execution risk, risk no more than 1-2% of total portfolio capital on this single trade unless you are expressly a high-risk trader.

Risks and counterarguments

• Weak pricing is the core operational risk. Management has explicitly cited lower antimony prices as a driver of the sales miss and guidance cut. If prices remain weak, margins and reported sales will continue to disappoint, undercutting any case for multiple expansion.
• Cash burn and negative free cash flow. The company is burning cash - free cash flow is negative about $71.3 million. That raises the chance that management must prioritize liquidity over buybacks or growth projects, which would be a market negative.
• Delivery timing and contract risk. Government orders can be lumpy and subject to timing shifts; the DLA backlog does not guarantee steady revenue recognition. Missed or delayed deliveries would quickly reverse sentiment.
• High short interest and volatile trading. While large short interest can create upside squeeze potential, it also makes the stock highly volatile and prone to sharp swings on negative headlines.
• Execution and jurisdictional risk. The company operates multiple segments and facilities; metallurgical, logistical, or regulatory problems at any plant could hurt production and margins.

Counterargument to the trade: One could argue that the market is correctly pricing a structurally weak near-term revenue outlook. The guidance reduction to $60-75 million for the year and the substantial negative operating cash flow argue that, absent a strong and repeatable policy-driven pickup, the share price could fall further as investors mark to lower normalized revenues. In that view, this is not a buy until there is clear proof of sustainable revenue and margin improvement.

Conclusion and what would change my mind

My view is cautiously bullish for a mid-term swing: the strategic importance of antimony and the DLA pipeline create a clear path to a re-rating, but execution risk and weak pricing mean this is not a buy-and-forget stock. The trade outlined above seeks to capture asymmetric upside while capping downside via a tight stop.

I would change my stance to neutral or bearish if the company reports another quarter of sequentially declining realized prices, materially larger cash burn without a credible liquidity plan, or if deliveries under the DLA contract prove inconsistent. Conversely, I would add to or hold a position if the company reports two consecutive quarters of stable or improving realized antimony prices, positive operating cash flow, or a demonstrated stream of DLA revenue and order recognition that removes the timing uncertainty.

Trade plan recap: enter $4.73, stop $3.80, target $9.50, mid term (45 trading days). Size small; treat as high-risk, catalyst-driven swing.